NMDA Receptor Antagonist
Memantine for Cognitive Impairment in SLE
This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.
Procedure
Sleep Endoscopy for Obstructive Sleep Apnea
This trial is studying a new way to examine the upper airway in people with obstructive sleep apnea who are getting surgery for their sleep apnea. The study is finding out how well this new technique works and if it can help predict who will or will not respond to sleep apnea surgery.
Popular Filters
Trials for Lupus Patients
Monoclonal Antibodies
PF-06823859 for Systemic Lupus Erythematosus
This trial is researching if a drug, PF-06823859, is safe and effective for adults with CLE or SLE and skin symptoms. 48 participants will receive active study medicine or placebo for 65 weeks of study.
Mobile App Intervention for Childhood-Onset Lupus
This trial aims to see if a custom mobile app can help young people with lupus stay engaged in their medical care and manage depression. The study focuses on adolescents and young adults from the Bronx, ages 15-24. The app offers personalized support to help them keep up with health appointments and improve their mood.
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Trials for Type 1 Diabetes Patients
Cell Therapy
Islet Transplantation for Type 1 Diabetes
This trial will study whether islet cell transplantation can help people with type 1 diabetes who have trouble controlling their blood sugar, despite using standard insulin therapy and monitoring their blood sugar levels often.
Cell Therapy
Islet Cell Transplant for Type 1 Diabetes
This trial is testing if it's safe to transplant human islet cells to help control blood sugar in type 1 diabetes patients who have trouble controlling it. Early observations will also be made about if this treatment can help with hypoglycemia.
Islet Cell Transplantation
Islet Cell Transplant for Type 1 Diabetes
This trial is testing whether islet transplantation is safe for people with Type 1 diabetes. Islets are clusters of cells that produce insulin, and the trial will use islets from cadaver donors.
Phase 3 Trials
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Anti-malarial drug
Stopping Hydroxychloroquine for Lupus
This trial is testing if older lupus patients can safely stop taking Hydroxychloroquine, a drug that reduces lupus symptoms but can harm the eyes over time. The study focuses on patients aged 60 and above who have stable disease. Researchers will monitor these patients for an extended period to see if their condition remains stable without the drug.
Trials With No Placebo
Mobile App Intervention for Childhood-Onset Lupus
This trial aims to see if a custom mobile app can help young people with lupus stay engaged in their medical care and manage depression. The study focuses on adolescents and young adults from the Bronx, ages 15-24. The app offers personalized support to help them keep up with health appointments and improve their mood.
Behavioral Intervention
Chronic Disease Self-Management Program for Systemic Lupus Erythematosus
This trial examines if a health education program can improve health and reduce healthcare use in African American women with lupus. The program involves regular sessions that teach practical skills for managing health problems. Researchers want to see if this helps these women better manage their condition. This community-based education program is designed to help participants gain confidence and skills to better manage their chronic conditions; it has been implemented worldwide.
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
View More Related Trials
Frequently Asked Questions
Introduction to sle
What are the top hospitals conducting sle research?
When it comes to advancing the understanding and treatment of Systemic Lupus Erythematosus (SLE), several top hospitals are leading the way with their clinical trials. In Nashville, Vanderbilt University Medical Center is making strides with five ongoing SLE trials and a total of six completed trials since they began their first recorded trial in 2017. Moving north to Chicago, Northwestern University has been actively involved in this research field as well, currently conducting four active SLE trials alongside an impressive history of 14 completed studies dating back to their inaugural trial in 2002.
Meanwhile, the renowned Mayo Clinic located in Rochester also plays a significant role by contributing valuable insights through its four ongoing SLE trials and involvement in five prior investigations spanning from as early as 1995. Washington University School of Medicine situated in Saint Louis demonstrates dedication towards addressing SLE through three current clinical trials while adding depth to this commitment with six previous studies conducted since initiating their initial trial back in 2013.
Adding itself to this list is NYU Langone Health based out of New york City where researchers are currently engaging with three active clinical tests focusing on SLE; interestingly theirs marks a new era being traced back only two years ago from2023 when they first launched their pioneering investigation into these cases.
These hospitals serve as vital contributors toward fighting against systemic lupus erythematosus, a complex autoimmune condition that affects multiple organs and systems within the body. Through cutting-edge research and innovative clinical trials conducted at these institutions across different locations, patients affected by SLE can find hope for improved treatments and ultimately better quality of life. Their collective efforts symbolize progress toward unraveling the mysteries surrounding this challenging disease
Which are the best cities for sle clinical trials?
When it comes to clinical trials for systemic lupus erythematosus (SLE), several cities in the United States are at the forefront of research. New york, with its 20 active trials, explores treatments such as Hydroxychloroquine (HCQ) and Administration of CC-97540 among others. Following closely behind is Houston, Texas, with 19 ongoing studies focusing on interventions like Cenerimod 4 mg and ALPN-101. Chicago, Illinois also plays a significant role in SLE research with 14 active trials investigating treatments including Dupilumab and BIIB059 High Dose. These cities provide valuable opportunities for individuals seeking participation in cutting-edge SLE clinical trials that may lead to improved treatment options and better outcomes.
Which are the top treatments for sle being explored in clinical trials?
In the realm of systemic lupus erythematosus (SLE) clinical trials, one treatment has emerged as a frontrunner: Cenerimod 4 mg. This cutting-edge drug is currently being explored in two active SLE trials and marks its debut in 2018 with only one all-time SLE trial to date. With ongoing research and development, Cenerimod holds great promise for revolutionizing the treatment landscape for SLE patients worldwide.
What are the most recent clinical trials for sle?
Recent clinical trials offer hope for individuals living with systemic lupus erythematosus (SLE), as innovative treatments and interventions are being explored. One notable trial is investigating the effectiveness of dupilumab, a medication that shows promise in managing SLE symptoms. Additionally, another study focuses on the administration of CC-97540, aiming to identify its potential benefits in treating this complex autoimmune disease. Furthermore, a Phase 2 trial referred to as Group 1 aims to evaluate an experimental intervention specifically designed for SLE patients. Another promising avenue lies in cenerimod 4 mg, which is undergoing Phase 3 testing for its efficacy against SLE symptoms. Lastly, researchers are exploring the impact of health communication messages on improving outcomes for individuals with SLE through a combined Phase 1 and Phase 2 study. With these diverse investigations underway, advancements towards better management and treatment options for SLE appear within reach.
What sle clinical trials were recently completed?
Recently, several clinical trials investigating potential treatments for systemic lupus erythematosus (SLE) have been successfully completed. Notably, in February 2022, Daiichi Sankyo concluded a trial studying DS-7011a's effectiveness. Earlier, Viela Bio's trial on VIB7734 was finalized in June 2021 while Sanofi wrapped up their SAR443122 trial in April 2021. Eli Lilly and Company also completed a study on LY3471851 back in August 2020. These trials represent significant strides towards finding better therapies for SLE patients and highlight the ongoing commitment of various pharmaceutical companies to tackle this challenging autoimmune disease head-on.